Phase 2 Study of RAY1225 Given by Injection to Adults with Obesity Evaluating Safety, Tolerability, and Effectiveness Compared to Placebo

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of RAY1225 in adults with obesity. This phase 2 study aims to learn about how well participants tolerate RAY1225 and also explores how it may help with weight loss. The study is expected to last about six months for each participant and is sponsored by Guangdong Raynovent Biotech Co., Ltd. Participants will be randomly assigned to receive either one of two doses of RAY1225 or a placebo. The treatments are given by subcutaneous injection once every two weeks for 24 weeks. There are two groups receiving escalating doses of RAY1225 and two placebo groups, all following the same dosing schedule. During the study, participants will be monitored for changes in body weight and waist circumference from the start of the study to week 26. Researchers will also track the percentage of participants who achieve weight loss of 5%, 10%, or 15%. Assessments will include safety and tolerability evaluations throughout the treatment period. The total participation time for each person is about six months.

A Study of RAY1225 in Participants With Obesity